Conferences
B
Advertisement
Advertisement
Trending on PharmExec
1
Nimbus Therapeutics and Eli Lilly Enter $1.3 Billion License Agreement and Research Collaboration for Oral Obesity Treatments
2
Amgen Acquires Dark Blue Therapeutics in $840 Million Transaction
3
Novo Nordisk’s Wegovy Pill Becomes First Oral GLP-1 Available in U.S.
4
Parental Control: Why Pharma’s Strongest Asset May Be Its Parent Brand
5